Lunit Collaborates with MD Anderson Cancer Center on 'Lunit Scope IO' Research

Medical AI company Lunit announced on the 27th that it has signed a research agreement with the MD Anderson Cancer Center, affiliated with the University of Texas Medical School, a world-renowned cancer treatment hospital in the United States, to analyze the therapeutic effects of MSD's immuno-oncology drug Keytruda (generic name pembrolizumab) across various cancer types.

Lunit's 'Lunit Scope IO'
[Photo by Lunit]

Lunit plans to utilize its independently developed AI biomarker, Lunit SCOPE IO, in this study conducted together with Dr. Aung Naing of the MD Anderson Cancer Center. The research aims to apply the AI-based Lunit SCOPE IO to MSD's clinical data to improve patient data analysis and evaluate AI technology to enhance the therapeutic effects of pembrolizumab in patients with various types of cancer.

Lunit SCOPE IO is an AI model trained on over 500,000 H&E slide images and more than 10 million cancer cells, detecting cancer regions, stroma, and tumor-infiltrating lymphocytes (TILs), immune cells that play a crucial role in immunotherapy. It also measures TIL density within the tumor microenvironment to generate immune phenotypes (IP) and serves as a new AI-based biomarker analyzing more than 16 types of cancer.

Seobum Seok, CEO of Lunit, stated, “In a situation where biomarkers to predict the therapeutic effects of immuno-oncology drugs, which have recently gained attention as next-generation anticancer agents, are lacking, there is increasing demand for the development of new biomarkers through advanced technologies such as AI. Especially through biomarker analysis of Keytruda, a representative immuno-oncology drug, in collaboration with MD Anderson, a global top-tier cancer treatment hospital, we expect to provide more effective treatment strategies for cancer patients.”

This content was produced with the assistance of AI translation services.